Corcept Therapeutics (CORT) Institutional Ownership
13F filers reported holding 75.3% of Corcept Therapeutics (CORT) shares as of Sep 30, 2026, across 503 filers.
- Held by 13F filers
- 75.3%
- Sep 30, 2026
- 13F filers
- 503
- quarter ended Sep 30, 2026
- 13F value
- $9.5B
- 82.5M shares
- Quarter's fund flow
- Mild accumulation
- 122 new · 37 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Swisher Daniel N JR | director | Acquired · Option exercise | 1,100 | $14.08 | ↗ |
| Nov 10, 2026 | Swisher Daniel N JR | director | Acquired · Option exercise | 400 | $10.50 | ↗ |
| Nov 10, 2026 | Swisher Daniel N JR | director | Disposed · Open-market sale | 1,500 | $74.07 | ↗ |
| Nov 10, 2026 | Swisher Daniel N JR | director | Disposed · Option exercise | 1,100Stock Option (right to buy) | — | ↗ |
| Nov 10, 2026 | Swisher Daniel N JR | director | Disposed · Option exercise | 400Stock Option (right to buy) | — | ↗ |
| Nov 3, 2026 | Maduck Sean | other | Acquired · Option exercise | 13,159 | $8.27 | ↗ |
| Nov 3, 2026 | Maduck Sean | other | Disposed · Open-market sale | 8,617 | $82.02 | ↗ |
| Nov 3, 2026 | Maduck Sean | other | Disposed · Open-market sale | 4,542 | $82.68 | ↗ |
| Nov 3, 2026 | Maduck Sean | other | Disposed · Option exercise | 13,159Stock option (right to buy) | — | ↗ |
| Nov 2, 2026 | Maduck Sean | other | Acquired · Option exercise | 11,841 | $8.27 | ↗ |
| Nov 2, 2026 | Maduck Sean | other | Disposed · Open-market sale | 11,841 | $81.42 | ↗ |
| Nov 2, 2026 | Maduck Sean | other | Disposed · Option exercise | 11,841Stock option (right to buy) | — | ↗ |
| Nov 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Acquired · Option exercise | 8,333 | $21.63 | ↗ |
| Nov 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Disposed · Open-market sale | 6,657 | $80.73 | ↗ |
| Nov 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Disposed · Open-market sale | 1,676 | $81.52 | ↗ |
| Nov 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Disposed · Option exercise | 8,333Stock option (right to buy) | — | ↗ |
| Oct 15, 2026 | WILSON JAMES N | director | Disposed · Open-market sale | 6,654 | $114.48 | ↗ |
| Oct 15, 2026 | WILSON JAMES N | director | Disposed · Open-market sale | 3,046 | $115.39 | ↗ |
| Oct 15, 2026 | WILSON JAMES N | director | Disposed · Open-market sale | 300 | $116.30 | ↗ |
| Oct 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Acquired · Option exercise | 8,333 | $21.63 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Corcept Therapeutics do institutions hold?
13F filers reported holding 75.3% of Corcept Therapeutics' shares as of Sep 30, 2026, across 503 filers.
How many 13F filers hold Corcept Therapeutics?
Corcept Therapeutics was held by 503 13F filers as of Sep 30, 2026.
Not investment advice.

